NCT06647329View on ClinicalTrials.gov

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
CAR-T Cell TherapyLymphomas
Interventions
BIOLOGICAL

CAR-T Therapy

CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas

Trial Locations (1)

470000

the First Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Mingzhi Zhang

OTHER

NCT06647329 - CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors | Biotech Hunter | Biotech Hunter